Alpha-synuclein — the protein that forms toxic clumps in the brains of people with Parkinson’s disease — may travel from enteroendocrine cells lining the gut to the brain through the vagus nerve, according to a study aiming to build on previous evidence of a gut-brain axis in Parkinson’s.
A ceramic blanket, a device being developed by Gladiator Therapeutics to improve blood flow and speed up wound healing, improved motor performance in a mouse model of Parkinson’s disease in a recent study. Besides improving balance and movement, the blanket also resulted in an increased number of cells…
Vanqua Bio will initiate clinical development of VQ-101 — a small molecule capable of penetrating the brain — in the first quarter of 2024, the company announced. The clinical testing will involve both healthy volunteers and individuals with Parkinson’s disease associated with mutations in the GBA gene.
Low-dose fosgonimeton (ATH-1017), an investigational small molecule, may have cognitive benefits for people with Parkinson’s disease-related dementia or dementia with Lewy bodies, according to recent data from a clinical trial. The small exploratory Phase 2 study, called SHAPE (NCT04831281), tested the safety and efficacy of fosgonimeton given once…
Phasing out fossil fuels could save an estimated 5.1 million lives each year worldwide by preventing deaths attributed to ambient air pollution, including those likely due to neurodegenerative diseases such as Parkinson’s, a study has found. Transitioning to clean, renewable energy sources is not only an effective intervention to…
People with Parkinson’s disease who maintain the recommended level of weekly physical activity tend to be those with critical health literacy, or the ability to understand health information and apply it in decisions regarding their well-being, a survey study reports. Offering targeted education about exercise and physical activity…
Some molecular changes that drive damage to brain cells in Parkinson’s disease take place in skin cells too, a study has found, adding to evidence that examining the skin may support an early diagnosis. Because skin cells are much easier to collect than brain cells, they also could be…
A Phase 1/2 clinical trial testing AAV-GAD, an investigational gene therapy being developed by MeiraGTx for Parkinson’s disease, is expected to be fully enrolled before the end of the year, the company announced in a press release. The placebo-controlled trial (NCT05603312), which began dosing last…
Positron emission tomography (PET) scans of the heart can help to identify people, known to be at risk for Parkinson’s disease or Lewy body dementia, up to seven years before they go on to develop these disorders, a small study suggests. In the National Institutes of Health (NIH)…
Mission Therapeutics’ experimental oral therapy MTX325, for Parkinson’s disease, spurred brain cells in mice to clear damaged mitochondria — the powerhouses of the cells — ultimately protecting them from death caused by toxic alpha-synuclein protein clumping. That’s according to the findings of a new study using a Parkinson’s…
Get regular updates to your inbox.
